Sleep disturbance is common in patients with GERD but there has been little evaluation of this problem in primary care in patients already taking therapy.
Dr Moayyedi and colleagues evaluated the impact of administering a questionnaire to identify patients with sleep problems, and evaluate the efficacy of esomeprazole to improve sleep disturbance in patients with GERD.
The team reported that this was a primary care based cluster-randomized, open-label study where practices were assigned to intervention or control groups.
PASS test failures continued current therapy or were switched to 4 weeks' once-daily esomeprazole 20 or 40 mg.
|120 of 534 of intervention patients reported continued sleep disturbance |
|Alimentary Pharmacology & Therapeutics|
The doctors noted that patients were evaluated at the end of 4 weeks, and the outcomes that were assessed were the sleep questions from the Quality of Life in Reflux and Dyspepsia questionnaire and the presence or absence of sleep disturbance from the PASS test questionnaire.
A total of 1388 patients with evaluable data at 4 weeks were included in the analysis, and 825 reported GERD-related sleep disturbance at baseline.
The research team found that at 4 weeks, 161 of 291 of control patients reported continued sleep disturbance compared to 120 of 534 of intervention patients.
There was a mean improvement in Quality of Life in Reflux and Dyspepsia scores related to sleep in the intervention patients compared to control patients.
Dr Moayyedi's team concluded, "A PASS strategy identifies GERD patients with sleep disturbance in primary care that will benefit from a change in acid-suppressive."